Amarin Corp Plcuk (AMRN) Total Debt Growth (1y) (2012 - 2020)
Amarin Corp Plcuk (AMRN) Total Debt Growth (1y) (2012 - 2020) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Total Debt Growth (1y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
12.60% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
5.23% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
-5.51% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
8.38% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
40.96% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
-0.10% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
-11.13% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
3.78% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Amarin Corp Plcuk |
5.17 Bn |
5.00 Bn |
17.77 Mn |
- |
| Date | Value |
|---|
| Sep 30, 2020 |
-84.23% |
| Jun 30, 2020 |
-67.27% |
| Mar 31, 2020 |
-50.23% |
| Dec 31, 2019 |
-37.61% |
| Sep 30, 2019 |
104.38% |
| Jun 30, 2019 |
131.92% |
| Mar 31, 2019 |
39.09% |
| Dec 31, 2018 |
56.50% |
| Sep 30, 2018 |
0.76% |
| Jun 30, 2018 |
-62.90% |
| Mar 31, 2018 |
-46.27% |
| Dec 31, 2017 |
-48.92% |
| Sep 30, 2017 |
116.44% |
| Jun 30, 2017 |
-49.04% |
| Mar 31, 2017 |
-5.09% |
| Dec 31, 2016 |
-32.64% |
| Sep 30, 2016 |
-87.17% |
| Jun 30, 2016 |
47.71% |
| Mar 31, 2016 |
-23.71% |
| Dec 31, 2015 |
8.72% |
